MRK - Context Therapeutics: Acquired Asset CT-95 Could Enhance T-Cell Engager Pipeline

2024-07-10 14:06:41 ET

Summary

• Context Therapeutics Inc.'s acquisition of CT-95, targeting MSLN expressing solid tumors, brings another shot on goal for its pipeline of T cell engagers.
• CTIM-76 is another T cell engager in the pipeline; however, it is being developed to go after oncofetal protein CLDN6, which is only highly expressed in embryonic tissue.
• With both phase 1 studies of CT-95 and CTIM-76 underway soon, it is highly likely that preliminary data from both trials could be released in 2025.
• Other T cell engager development companies have not only established proof of concept, but have shown this type of immunotherapy to be safe with low incidence of ? G3 CRS.

Context Therapeutics Inc. ( CNTX ) just announced the acquisition of a phase 1 ready asset T-cell engager known as CT-95, which was formerly owned by Link Immunotherapeutics, Inc. [Link]. This asset is a mesothelin [MSLN] and CD3 T cell engaging bispecific antibody targeting mesothelin tumor types. The premise of the acquisition of such an asset would be because it has the potential to be both first-in-class and best-in-class in targeting such tumor types. A catalyst for investors to look forward to would be that a phase 1 study, using CT-95 for the treatment of patients with MSLN expressing tumors, is expected to begin in Q1 of 2025....

For further details see: